수의용 안과 의약품 시장 규모, 점유율, 동향 분석 보고서 : 동물별, 약물별, 적응증별, 유통 채널별, 지역별, 부문별 예측(2026-2033년)

Veterinary Ophthalmic Drugs Market Summary

The global veterinary ophthalmic drugs market size was estimated at USD 2.1 billion in 2025 and is projected to reach USD 3.6 billion by 2033, growing at a CAGR of 7.1% from 2026 to 2033. Some of the factors driving the market growth are advancements in ophthalmic drug-delivery technologies, rising development of long-acting ophthalmic therapies, increasing focus on antimicrobial stewardship & evidence-based use, and growing clinical demand for treatment of complex ocular diseases.

Advances in drug delivery technology are driving market growth. Advanced technologies such as artificial intelligence are improving corneal drug delivery by modeling how formulation variables affect ocular absorption and retention. A February 2026 review from the University of Illinois Chicago, published in MDPI, reported that machine learning predicts particle size, release kinetics, corneal permeability, and irritation risk before laboratory validation. These models operate in closed-loop systems that refine formulations using experimental feedback. The approach reduces development time, supports safer carrier design, and enables smart platforms such as peptide carriers and drug-releasing contact lenses. This shift is creating growth opportunities for precision-based ophthalmic therapies with sustained release profiles.

Furthermore, an April 2025 study conducted at the Hebrew University of Jerusalem reported that eyedrops formulated with cross-linked hyaluronic acid achieved superior ocular bioavailability than conventional carriers. Dogs treated with XHA-based drops recorded 2.4 times higher exposure to cefazolin and 4.2 times higher exposure to chloramphenicol compared with polyvinyl alcohol formulations. Higher drug exposure and prolonged retention on the corneal surface reduce dosing frequency and improve treatment adherence among pet owners. Lower administration burden increases the acceptance of premium ophthalmic therapies in clinical practice.

Moreover, an April 2025 article published on Drugs.com confirmed that hyaluronic acid carriers extend antibiotic residence time on canine ocular tissue and may reduce the risk of antimicrobial resistance. The report noted that hyaluronic acid supports epithelial healing and exhibits mild antimicrobial activity. Veterinary pharmaceutical companies are responding by developing combination products that integrate antibiotics with advanced viscoelastic carriers. These platforms create opportunities for antifungal therapies, immunomodulators, and anti-glaucoma agents that benefit from sustained ocular exposure.

Drug delivery innovation has emerged as the most decisive market growth. Artificial intelligence-led formulation design and advanced carriers such as cross-linked hyaluronic acid are increasing ocular drug exposure and extending therapeutic duration beyond conventional drops. Veterinary clinics are prioritizing products that achieve measurable clinical improvement with fewer daily doses and lower resistance risk. Manufacturers are directing capital toward differentiated delivery platforms that command premium pricing and strengthen brand positioning against generics. This technology-centered shift is accelerating demand in chronic indications such as keratoconjunctivitis sicca and glaucoma and is shaping the long-term expansion trajectory of the sector.

Global Veterinary Ophthalmic Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global veterinary ophthalmic drugs market report based on animal, drug, indication, distribution channel, and region

• Animal Outlook (Revenue, USD Million, 2021 - 2033)
• Canine
• Feline
• Equine
• Bovine
• Others
• Drug Outlook (Revenue, USD Million, 2021 - 2033)
• Antibiotics
• NSAIDs
• Corticosteroids
• Lubricants / Artificial Tears
• Analgesics / Pain Relievers
• Others Drugs
• Indication Outlook (Revenue, USD Million, 2021 - 2033)
• Eyelid Abnormalities
• Cataract
• Glaucoma
• Retinal Complications
• Uveitis
• Conjunctivitis
• Corneal Complications
• Other Indications
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Veterinary Hospitals & Clinics
• Specialty Stores
• E-Commerce
• Other Distribution Channels
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • India
  • China
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Qatar
  • Oman

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definition
  • 1.2.1. Animal
  • 1.2.2. Drug
  • 1.2.3. Indication
  • 1.2.4. Distribution Channel
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information/Data Analysis
• 1.6. Market Formulation & Visualization
• 1.7. Data Validation & Publishing
• 1.8. Model Details
  • 1.8.1. Model 1 Analysis
  • 1.8.2. Model 2 Analysis
  • 1.8.3. Model 3 Analysis
  • 1.8.4. Global Market: CAGR Calculation
• 1.9. List of Secondary Sources
• 1.10. List Of Abbreviations
• 1.11. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Veterinary Ophthalmic Drugs Market Variable Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market
  • 3.1.2. Ancillary Market
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Advancements in Ophthalmic Drug-Delivery Technologies
    • 3.2.1.2. Rising Development of Long-Acting Ophthalmic Therapies
    • 3.2.1.3. Increasing Focus on Antimicrobial Stewardship & Evidence-Based Use
    • 3.2.1.4. Growing Clinical Demand for Treatment of Complex Ocular Diseases
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Regulatory Restrictions on Antibiotic Use in Animals
    • 3.2.2.2. Limited Standardized Guidelines for Ophthalmic Antibiotic Prescribing
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenge Analysis
• 3.3. Veterinary Ophthalmic Drugs Market Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis, by SWOT
  • 3.3.3. Pricing Analysis
  • 3.3.4. Estimated Animal Population by region, key species, 2025

Chapter 4. Veterinary Ophthalmic Drugs Market: Animal Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Veterinary Ophthalmic Drugs Market: Animal Movement Analysis
• 4.3. Veterinary Ophthalmic Drugs Market Size & Trend Analysis, by animal, 2021 to 2033 (USD Million)
• 4.4. Canine
  • 4.4.1. Canine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Feline
  • 4.5.1. Feline Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Equine
  • 4.6.1. Equine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Bovine
  • 4.7.1. Bovine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.8. Other Animals
  • 4.8.1. Other Animals Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Veterinary Ophthalmic Drugs Market: Drug Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Veterinary Ophthalmic Drugs Market: Drug Movement Analysis
• 5.3. Veterinary Ophthalmic Drugs Market Size & Trend Analysis, by Drug, 2021 to 2033 (USD Million)
• 5.4. Antibiotics
  • 5.4.1. Antibiotics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. NSAIDs
  • 5.5.1. NSAIDs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Corticosteroids
  • 5.6.1. Corticosteroids Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Lubricants / Artificial Tears
  • 5.7.1. Lubricants / Artificial Tears Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Analgesics / Pain Relievers
  • 5.8.1. Analgesics / Pain Relievers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.9. Others Drugs
  • 5.9.1. Others Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Veterinary Ophthalmic Drugs Market: By Indication Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Veterinary Ophthalmic Drugs Market: By Indication Movement Analysis
• 6.3. Veterinary Ophthalmic Drugs Market Size & Trend Analysis, by Indication, 2021 to 2033 (USD Million)
  • 6.3.1. Eyelid Abnormalities
    • 6.3.1.1. Eyelid Abnormalities Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.2. Cataract
    • 6.3.2.1. Cataract Care Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.3. Glaucoma
    • 6.3.3.1. Glaucoma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.4. Retinal Complications
    • 6.3.4.1. Retinal Complications Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.5. Uveitis
    • 6.3.5.1. Uveitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.6. Conjunctivitis
    • 6.3.6.1. Conjunctivitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.7. Corneal Complications
    • 6.3.7.1. Corneal Complications Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3.8. Other Indications
    • 6.3.8.1. Other Indications Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Veterinary Ophthalmic Drugs Market: By Distribution Channel Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Veterinary Ophthalmic Drugs Market: By Distribution Channel Movement Analysis
• 7.3. Veterinary Ophthalmic Drugs Market Size & Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
  • 7.3.1. Veterinary Hospitals & Clinics
    • 7.3.1.1. Veterinary Hospitals & Clinics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.2. Specialty Stores
    • 7.3.2.1. Specialty Stores Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.3. E-Commerce
    • 7.3.3.1. E-Commerce Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.4. Other Distribution Channels
    • 7.3.4.1. Other Distribution Channels Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Veterinary Ophthalmic Drugs Market: Regional Estimates & Trend Analysis

• 8.1. Regional Dashboard
• 8.2. Veterinary Ophthalmic Drugs Market Share, By Region, 2025 & 2033 (USD Million)
• 8.3. Regional Outlook
• 8.4. North America
  • 8.4.1. North America Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. U.S. Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Canada Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Mexico Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. UK Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Germany Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. France Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Italy Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Spain Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. Denmark
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Denmark Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Competitive Scenario
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Sweden Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.5.9. Norway
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Competitive Scenario
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Norway Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Japan Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. China Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. India Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.6.5. Australia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Australia Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Competitive Scenario
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. South Korea Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Competitive Scenario
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Thailand Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Brazil Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Argentina Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
• 8.8. Middle East & Africa
  • 8.8.1. Middle East & Africa Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Competitive Scenario
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. South Africa Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Competitive Scenario
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Saudi Arabia Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Competitive Scenario
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. UAE Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Competitive Scenario
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Kuwait Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.8.6. Qatar
    • 8.8.6.1. Key Country Dynamics
    • 8.8.6.2. Competitive Scenario
    • 8.8.6.3. Regulatory Framework
    • 8.8.6.4. Qatar Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.8.7. Oman
    • 8.8.7.1. Key Country Dynamics
    • 8.8.7.2. Competitive Scenario
    • 8.8.7.3. Regulatory Framework
    • 8.8.7.4. Oman Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
• 9.2. Company Market Position Analysis/ Heat Map Analysis, 2025
• 9.3. Company Profiles
  • 9.3.1. Merck & Co., Inc.
    • 9.3.1.1. Participant's Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Product Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Zoetis
    • 9.3.2.1. Participant's Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Product Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Dechra Pharmaceuticals
    • 9.3.3.1. Participant's Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Product Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. Virbac
    • 9.3.4.1. Participant's Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Product Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Ceva Sante Animale
    • 9.3.5.1. Participant's Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Product Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Elanco
    • 9.3.6.1. Participant's Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Product Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Bausch & Lomb
    • 9.3.7.1. Participant's Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Product Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. Sandoz
    • 9.3.8.1. Participant's Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Product Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. Norbrook Laboratories
    • 9.3.9.1. Participant's Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Product Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. I-Med Animal Health
    • 9.3.10.1. Participant's Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Product Benchmarking
    • 9.3.10.4. Strategic Initiatives
  • 9.3.11. Domes Pharma, Inc.
    • 9.3.11.1. Participant's Overview
    • 9.3.11.2. Financial Performance
    • 9.3.11.3. Product Benchmarking
    • 9.3.11.4. Strategic Initiatives